The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
01-Jun-16
$221 million
Target:
Patties Foods Ltd
Acquiror:
Pacific Equity Partners
Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
16-Mar-16
$942 million
Target:
Rofin-Sinar Technologies, Inc.
Acquiror:
Coherent, Inc.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
26-Feb-16
$NA
Target:
Policard
Acquiror:
Groupe Up
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
21-Dec-15
$NA
Target:
Antin Solar Investments
Acquiror:
Quercus Investment Partners / Swiss Life Asset Management
Advised Antin Infrastructure Partners on its sale of Antin Solar Investments, a leading Italian solar platform, to a consortium of investors comprised of Swiss Life Asset Management and Quercus Investment Partners
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
14-Dec-15
$NA
Target:
Specialized Anodized Extrusion Holding Switzerland AG (Spandex)
Acquiror:
Chequers Capital
Advised Gilde Buy Out Partners on the sale of Spandex, a specialized B2B distributor of graphic media and equipment to the signage and visual communications industry, to Chequers Capital
07-Dec-15
$755 million
Target:
Stork
Acquiror:
Fluor Corporation
Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
07-Aug-15
$NA
Target:
Victorian Thoroughbred Racing Media Rights
Acquiror:
Tabcorp Holdings Limited
Advised Tabcorp Holdings Limited (“Tabcorp”), a leading diversified Australian entertainment group with wagering, gaming, racing media and Keno operations, on reaching agreement on a long-term deal for domestic broadcast, digital and international media rights for Victorian thoroughbred racing content
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
29-May-15
$4.1 billion
Target:
Telecity Group plc
Acquiror:
Equinix, Inc.
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally
03-Mar-15
$66 million
Target:
The Warehouse Group Limited
Advised Woolworths Limited, Australia’s largest supermarket operator, on strategic options for the divestment of its 8.8% holding in The Warehouse Group, New Zealand’s largest general merchandise retailer
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
14-Jan-15
$309 million
Target:
Chandler Macleod Group Limited
Acquiror:
Recruit Holdings Co.,Ltd
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Chandler Macleod Group Limited, a major general recruitment company
14-Jan-15
$55 million
Target:
Peoplebank Holdings PTY LTD
Acquiror:
Recruit Holdings Co.,Ltd
Advised Recruit Holdings Co.,Ltd, the leading global staffing services company in Japan, on the acquisition of Peoplebank Holdings PTY LTD, Australasia’s leading IT&T recruitment company
12-Aug-14
$NA
Target:
Faster S.p.A.
Acquiror:
Capvis
Advised Capvis, one of the leading buyout firms in Switzerland, on the acquisition of Faster S.p.A., one of the top 2 global manufacturers of quick-release hydraulic couplings
11-Aug-14
$NA
Target:
MannKind Corporation
Acquiror:
Sanofi
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
10-Apr-14
$NA
Target:
Flint Group
Acquiror:
Consortium of Goldman Sachs MBD and Koch Industries
Advised Flint Group, a portfolio company of CVC Capital Partners and a global leader in the manufacturing of printing inks and consumables on its sale to a consortium consisting of Goldman Sachs Merchant Banking and the private equity arm of Koch Industries
08-Apr-14
$NA
Target:
ARTnews
Acquiror:
Skate Capital Corp.
Advised ARTnews, the world's oldest and most widely circulated art magazine, on its sale to Skate Capital Corp., a private art and media industry investment vehicle
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
05-Feb-14
$NA
Target:
Unfors Raysafe AB
Acquiror:
Fluke Biomedical Corporation
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products